<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Behav. Neurosci.</journal-id>
<journal-title>Frontiers in Behavioral Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Behav. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5153</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnbeh.2020.00066</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Behavioral Neuroscience</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Attention and Methylphenidate</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Avital</surname> <given-names>Avi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/257709/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Manor</surname> <given-names>Iris</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/459474/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Coghill</surname> <given-names>David</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/424267/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neuroscience, Rappaport Faculty of Medicine, Emek Medical Center, Technion - Israel Institute of Technology</institution>, <addr-line>Haifa</addr-line>, <country>Israel</country></aff>
<aff id="aff2"><sup>2</sup><institution>ADHD Clinic, Geha MHC and Clalit, Sackler School of Medicine</institution>, <addr-line>Tel Aviv</addr-line>, <country>Israel</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Nuno Sousa, University of Minho, Portugal</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Avi Avital <email>Avital&#x00040;technion.ac.il</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Emotion Regulation and Processing, a section of the journal Frontiers in Behavioral Neuroscience</p></fn></author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>14</volume>
<elocation-id>66</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>04</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>04</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2020 Avital, Manor and Coghill.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Avital, Manor and Coghill</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/8495/attention-and-methylphenidate" ext-link-type="uri">Editorial on the Research Topic <article-title>Attention and Methylphenidate</article-title></related-article> <kwd-group>
<kwd>ADHD</kwd>
<kwd>diagnosis</kwd>
<kwd>methylphenidate</kwd>
<kwd>adherence</kwd>
<kwd>anxiety</kwd>
<kwd>dysregulation</kwd>
<kwd>dose</kwd>
<kwd>non-responder</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="9"/>
<page-count count="3"/>
<word-count count="1629"/>
</counts>
</article-meta>
</front>
<body>
<p>Attention Deficit Hyperactivit Disorder, more simply known as ADHD, is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. There are three major presentations: primarily hyperactive and impulsive, primarily inattentive, and combined type (Gaub and Carlson, <xref ref-type="bibr" rid="B1">1997</xref>). However, despite the differences between the subtypes, methylphenidate (MPH), a psychostimulant, is the primary pharmaceutical treatment of choice (Heal et al., <xref ref-type="bibr" rid="B2">2009</xref>).</p>
<p>While MPH is largely an effective treatment across the subtypes (O&#x00027;Driscoll et al., <xref ref-type="bibr" rid="B5">2005</xref>), there is a large issue with adherence to treatment. In her contribution, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnbeh.2019.00106">Kritchman et al.</ext-link> findings suggested that acute MPH administration induces a delayed anxiogenic response. Considering ADHD-anxiety comorbidity, acute doses of MPH can induce anxiety, while, paradoxically, chronic MPH treatment has anxiolytic effects (Zubedat et al., <xref ref-type="bibr" rid="B9">2019</xref>). There can be large difference in dose-response to MPH, even when a patient adheres to ADHD treatment. Additionally, some ADHD patients do not respond to medication at all, despite displaying typical ADHD symptoms. These &#x0201C;non-responders&#x0201D; may decrease adherence to MPH treatment, because they perceive the medication to be ineffective. The exact cause for non-responders is unknown, and it may stem from a puzzling, non-linear dose response to MPH.</p>
<p>The subset of ADHD non-responders may be mitigated with improved objective diagnostic assessments of ADHD. Throughout one&#x00027;s life, a variety of circumstances influence the individual&#x00027;s attention. For instance, high levels of stress, exhaustion and hunger, can all have large implications on attention, and are common dysregulating experiences throughout one&#x00027;s life. Since there are no sufficiently objective and accurate diagnostics for ADHD, subjects experiencing temporary inattention due to external circumstances may be misdiagnosed. These misdiagnoses could account for the number of non-responders to MPH treatment, as these &#x0201C;non-responders&#x0201D; could simply be patients suffering from transient inattention, rather than a true neurodevelopmental disorder. In the past 25 years the rates of ADHD diagnosis have increased (Mahone and Denckla, <xref ref-type="bibr" rid="B4">2017</xref>), and while this may be due to a true increase in ADHD rates, lack of objective diagnostic protocols can increase misdiagnosis.</p>
<p>While these disparities in dose-response are puzzling, many techniques may shed light on these issues. In her contribution, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyg.2019.01796">Wigal et al.</ext-link> described the Laboratory School Protocol (LSP), a research protocol in which students are placed in a classroom environment where they are medicated and their behavior is evaluated. In her contribution, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyg.2019.01817">Rinker et al.</ext-link> postulated that ADHD affects academic functioning regardless of education level; Thus, LSPs are applicable to ADHD regardless of education level. In LSPs, medication is given at the research site to control for temporal differences in application, elucidating on the large variation in dose-response to MPH in ADHD patients. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyg.2019.01796">Wigal et al.</ext-link> reported that placebo effects are reduced when research environments mirror situations in which symptoms would be aggravated and when medication administration is tightly controlled, altogether aiding in the establishment of more objective ADHD diagnostic tests.</p>
<p>LSPs utilize the Permanent Product Measure of Performance Math Test (PERMP) as the most objective ADHD diagnostic test to date. However, promising research regarding norepinephrine receptors could lead to objective diagnosis even outside of simulated classroom environments like the LSP and exams like the PERMP. In their commentary on van den Brink et al. (<xref ref-type="bibr" rid="B7">2018</xref>), <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnbeh.2019.00217">Medel et al.</ext-link> contributed that the differential expression of &#x003B1;1 and &#x003B1;2 norepinephrine (NE) receptors can induce heterogeneous spatial modes, a shifting of &#x0201C;brain states.&#x0201D; Thus, suggesting that there is a dynamic shaping of brain activity by neuromodulations through the heterogeneous expression of &#x003B1;1 and &#x003B1;2 NE receptors that creates spontaneous fluctuations in cognition, elucidating on data previously established by Shine et al. (<xref ref-type="bibr" rid="B6">2019</xref>). In her contributed mini-review, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyg.2019.01796">Wigal et al.</ext-link> further supports this suggestion by claiming that ADHD itself is not necessarily an attention deficit, but rather inconsistent and misdirected attention. Likewise, according to <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyg.2019.01043">Spiegel and Pollak</ext-link> contributed research, ADHD encompasses a lack of proper evaluation of risk-taking behavior. Hypothetically, those with ADHD do not necessarily have limited attention, but the attention is misdirected through varying brain states due to differential expression of &#x003B1;1 and &#x003B1;2 NE receptors. Practically, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnbeh.2019.00217">Medel et al.</ext-link> show that pupillometry can measure varying levels of NE with different brain states, establishing a possible objective diagnostic measure of ADHD. Together, pupillometry and the PERPM may prove to be a robust, objective diagnostic measure of ADHD, which may limit misdiagnosis in ADHD and the number of &#x0201C;non-responders&#x0201D; to ADHD treatment.</p>
<p>While MPH and behavioral therapies are available, there are prevention techniques which may help to reduce the development of ADHD altogether. Tapping the black box of ADHD on its translational face, previous reports utilizing animal models showed that the application of MPH alone and/or with enriched environment (EE) on adult offspring rescues the detrimental effects of prenatal stress attentional reactivity (Zubedat et al., <xref ref-type="bibr" rid="B8">2015</xref>). The influence of EE and MPH could be translated and confirmed by conducting LSP studies, hence, elucidating on ways EE may be increased in school systems to aid in ADHD symptoms.</p>
<p>Taken with these results, MPH has clinical applications outside of ADHD. Acute MPH improves cognitive ability in those with and without ADHD (Linssen et al., <xref ref-type="bibr" rid="B3">2014</xref>). Temporary use of MPH to improve cognition may be appropriate in professions where inattention has true large implications in the livelihood of others (e.g., medical doctors on extended shift). However, as previously mentioned, side effects such as temporarily increased anxiety must be taken into account when MPH is acutely administered.</p>
<p>In essence, adherence issues with MPH treatment in those with ADHD may be rooted in acute increases in anxiety, non-responders, and misdiagnosis. These adherence issues could be mediated by assuring patients anxiogenic effects are temporary. In order to accurately diagnose patients with ADHD, we must focus on discovering and implementing objective diagnostic measures such as pupillometry. In order to decrease ADHD diagnosis overall, we can increase research on potential prevention methods such as environmental enrichment, as well as on the effects of adverse life events, such as prenatal stress, on attention.</p>
<sec id="s1">
<title>Author Contributions</title>
<p>AA conceptualized and wrote the article. IM and DC consulted and edited the paper.</p>
</sec>
<sec id="s2">
<title>Conflict of Interest</title>
<p>Independent of this editorial DC has received research funding from Takeda/Shire, honoraria from Takeda/Shire, Medice and Servier. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack><p>The authors would like to thank all the investigators who contributed articles to this Research Topic. The authors would like to thank Ms. Anna Grossman for her assistance in preparing this editorial.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaub</surname> <given-names>M.</given-names></name> <name><surname>Carlson</surname> <given-names>C. L.</given-names></name></person-group> (<year>1997</year>). <article-title>Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population</article-title>. <source>J. Abnormal Child Psychol.</source> <volume>25</volume>, <fpage>103</fpage>&#x02013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1023/A:1025775311259</pub-id><pub-id pub-id-type="pmid">9109027</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heal</surname> <given-names>D. J.</given-names></name> <name><surname>Cheetham</surname> <given-names>S. C.</given-names></name> <name><surname>Smith</surname> <given-names>S. L.</given-names></name></person-group> (<year>2009</year>). <article-title>The neuropharmacology of ADHD drugs <italic>in vivo</italic>: insights on efficacy and safety</article-title>. <source>Neuropharmacology</source> <volume>57</volume>, <fpage>608</fpage>&#x02013;<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.08.020</pub-id><pub-id pub-id-type="pmid">19761781</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linssen</surname> <given-names>A. M. W.</given-names></name> <name><surname>Sambeth</surname> <given-names>A.</given-names></name> <name><surname>Vuurman</surname> <given-names>E. F. P. M.</given-names></name> <name><surname>Riedel</surname> <given-names>W. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies</article-title>. <source>Int. J. Neuropsychopharmacol.</source> <volume>17</volume>, <fpage>961</fpage>&#x02013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145713001594</pub-id><pub-id pub-id-type="pmid">24423151</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahone</surname> <given-names>E. M.</given-names></name> <name><surname>Denckla</surname> <given-names>M. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Initial opinions on the effects of Phenylbutazone (PBZ) and historical prospective</article-title>. <source>J. Int. Neuropsychol. Soc.</source> <volume>23</volume>, <fpage>916</fpage>&#x02013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1017/S1355617717000807</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x00027;Driscoll</surname> <given-names>G. A.</given-names></name> <name><surname>D&#x000E9;patie</surname> <given-names>L.</given-names></name> <name><surname>Holahan</surname> <given-names>A. L. V.</given-names></name> <name><surname>Savion-Lemieux</surname> <given-names>T.</given-names></name> <name><surname>Barr</surname> <given-names>R. G.</given-names></name> <name><surname>Jolicoeur</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder</article-title>. <source>Biol. Psychiatry</source> <volume>57</volume>, <fpage>1452</fpage>&#x02013;<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.02.029</pub-id><pub-id pub-id-type="pmid">15950020</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shine</surname> <given-names>J. M.</given-names></name> <name><surname>Breakspear</surname> <given-names>M.</given-names></name> <name><surname>Bell</surname> <given-names>P. T.</given-names></name> <name><surname>Martens</surname> <given-names>K. E.</given-names></name> <name><surname>Shine</surname> <given-names>R.</given-names></name> <name><surname>Koyejo</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Human cognition involves the dynamic integration of neural activity and neuromodulatory systems</article-title>. <source>Nat. Neurosci.</source> <volume>22</volume>, <fpage>289</fpage>&#x02013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-018-0312-0</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Brink</surname> <given-names>R. L.</given-names></name> <name><surname>Nieuwenhuis</surname> <given-names>S.</given-names></name> <name><surname>Donner</surname> <given-names>T. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Amplification and suppression of distinctbrainwide activity patterns by catecholamines</article-title>. <source>J. Neurosci.</source> <volume>38</volume>, <fpage>7476</fpage>&#x02013;<lpage>7491</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0514-18</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zubedat</surname> <given-names>S.</given-names></name> <name><surname>Aga-Mizrachi</surname> <given-names>S.</given-names></name> <name><surname>Cymerblit-Sabba</surname> <given-names>A.</given-names></name> <name><surname>Ritter</surname> <given-names>A.</given-names></name> <name><surname>Nachmani</surname> <given-names>M.</given-names></name> <name><surname>Avital</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Methylphenidate and environmental enrichment ameliorate the deleterious effects of prenatal stress on attention functioning</article-title>. <source>Stress</source> <volume>18</volume>, <fpage>280</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.3109/10253890.2015.1023790</pub-id><pub-id pub-id-type="pmid">25783195</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zubedat</surname> <given-names>S.</given-names></name> <name><surname>Havkin</surname> <given-names>E.</given-names></name> <name><surname>Maoz</surname> <given-names>I.</given-names></name> <name><surname>Aga-Mizrachi</surname> <given-names>S.</given-names></name> <name><surname>Avital</surname> <given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>A probabilistic model of startle response reveals opposite effects of acute versus chronic methylphenidate treatment</article-title>. <source>J. Neurosci. Methods</source> <volume>327</volume>:<fpage>108389</fpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2019.108389</pub-id><pub-id pub-id-type="pmid">31415846</pub-id></citation></ref>
</ref-list>
</back>
</article>